SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum

Rhea-AI Summary

SELLAS Life Sciences (NASDAQ: SLS) announced that Dr. Angelos Stergiou, President and CEO, will participate in the J.P. Morgan U.S. Opportunities Forum with 1x1 investor meetings on Wednesday, November 12, 2025 at the Kimpton EPIC Hotel in Miami, Florida.

The company will host one-on-one meetings; investors should register via J.P. Morgan or contact their J.P. Morgan representative for access.

Company to conduct 1x1 meetings with investors on Wednesday, November 12th  

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in the J.P. Morgan U.S. Opportunities Forum, which is being held on Wednesday, November 12, at the Kimpton EPIC Hotel in Miami, Florida.

J.P. Morgan U.S. Opportunities Forum Details:

Format: 1x1 investor meetings

Date: Wednesday, November 12, 2025

Location: Kimpton EPIC Hotel, Miami, FL

Registration Link: Click Here or please contact your J.P. Morgan representative

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact
John Fraunces
Managing Director
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

FAQ

When will SELLAS (SLS) meet investors at the J.P. Morgan U.S. Opportunities Forum?

SELLAS will conduct 1x1 investor meetings on Wednesday, November 12, 2025.

Who from SELLAS (SLS) will attend the J.P. Morgan U.S. Opportunities Forum?

Dr. Angelos Stergiou, President and CEO of SELLAS, will participate in the event.

Where is the J.P. Morgan U.S. Opportunities Forum that SELLAS (SLS) is attending?

The forum is at the Kimpton EPIC Hotel, Miami, Florida on November 12, 2025.

What is the meeting format for SELLAS (SLS) at the J.P. Morgan U.S. Opportunities Forum?

SELLAS will hold one-on-one (1x1) investor meetings during the forum.

How can investors register to meet SELLAS (SLS) at the November 12, 2025 forum?

Investors should register via J.P. Morgan's registration link or contact their J.P. Morgan representative.

Does SELLAS (SLS) disclose any financial or clinical details for the J.P. Morgan meeting on November 12, 2025?

The announcement only confirms attendance and 1x1 meetings; no financial or new clinical data were disclosed for the meeting.